Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Sanofi

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Sanofi's 2013 sales performance.

Sanofi

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a

Sanofi sells European generics to Advent for $2.4bn

Sanofi sells European generics to Advent for $2.4bn Sanofi sells European generics to Advent for $2.4bn. The deal will create a new, independent European generics company. ... Private equity group Advent has agreed a 1.9bn ($2.4bn) deal to buy the European generics unit of French pharma company Sanofi.

Sanofi backs vaccines unit with €350m Canadian facility

Sanofi backs vaccines unit with €350m Canadian facility Sanofi backs vaccines unit with 350m Canadian facility. The new plant will make paediatric and booster vaccines. ... Once completed in 2021, the new facility will also be equipped to produce diphtheria and tetanus antigens, said Sanofi.

Neurocentrx appoints two members to the board

Neurocentrx appoints two members to the board Brooksby brings experience in business and growth strategy across the healthcare sector having held senior global positions at Pfizer, Sanofi and Wellcome - now GSK.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics